Title
A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception
A Phase 3, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception
Phase
Phase 3Lead Sponsor
Medicines360Study Type
InterventionalStatus
Completed No Results PostedIndication/Condition
ContraceptionIntervention/Treatment
norgestrel ...Study Participants
1910The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception for up to 10 years.
This is a Phase 3, randomized, open-label, multicenter evaluation of the efficacy of a levonorgestrel-releasing intrauterine system (LNG20). The goals of the study include provision of information to understand efficacy and safety within the widest range of possible users of the LNG20. Typically, intrauterine contraceptive studies only include women 18-35 years of age for efficacy and safety, and place limits on parity and larger body size. Women outside of these characteristics also desire an effective intrauterine contraceptive. Accordingly, this study will include women who are both nulliparous and parous as well as women less than 18 years of age in the primary efficacy and safety analyses
levonorgestrel-releasing intrauterine system for contraception
Mirena intrauterine system
Inclusion Criteria: Healthy women requesting contraception 16-35 years old Cohort 36-45 years old Sexually active Exclusion Criteria: Currently pregnant, pregnant within 4 weeks prior to study entry or planning pregnancy within 24 months of study entry Currently breastfeeding Current persistent, abnormal vaginal bleeding
